V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330004078 | 330002021 | 1.7 | 89 | Curative (C) | 2014-07-13 | 2014-07-23 | CETUXIMAB | 02 | Y | 330015905 | CETUXIMAB |
| 330004079 | 330002021 | 1.68 | 56.8 | Palliative (P) | 2013-10-03 | 2013-10-16 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 330015905 | CISPLATIN + GEMCITABINE |
| 330004080 | 330002022 | 1.72 | 64.5 | null | 2015-05-07 | 2015-05-19 | CAP | 02 | N | 330015910 | CAP |
| 330004081 | 330002022 | 1.63 | 48 | Neo-adjuvant (N) | 2015-07-06 | 2015-07-07 | OST Euramos 1 Closed Trial - AP | N | N | 330015910 | MAP |
| 330004082 | 330002023 | 1.66 | 67 | Palliative (P) | null | 2013-03-05 | GEMCARBO | N | N | 330015927 | GEMCARBO |
| 330004083 | 330007105 | 1.62 | 60 | Adjuvant (A) | 2015-05-23 | 2015-05-23 | GemCarbo Days 1+8 | 02 | null | 330015930 | GEMCARBO |
| 330004084 | 330002024 | 1.74 | 62.1 | Not known (9) | 2013-10-08 | 2013-10-09 | GemCarbo Days 1+8 | N | N | 330015946 | GEMCARBO |
| 330004085 | 330002024 | null | 61 | Neo-adjuvant (N) | 2015-10-25 | 2015-11-01 | Cisplatin + Etoposide (3 day) | null | N | 330015946 | CISPLATIN + ETOPOSIDE |
| 330004086 | 330002024 | 1.87 | 60 | Not known (9) | 2016-12-14 | 2016-12-14 | Cyclophosphamide + Dex + Rituximab | N | N | 330015946 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330004087 | 330002024 | null | null | null | 2015-02-26 | 2015-03-19 | OST Euramos 1 Closed Trial - AP | null | N | 330015946 | MAP |
| 330004088 | 330002024 | 1.66 | 78.9 | Palliative (P) | 2017-05-19 | 2017-06-07 | CVP R | N | N | 330015946 | CVP R |
| 330004089 | 330012673 | 1.64 | null | Neo-adjuvant (N) | 2013-06-09 | 2013-06-20 | EW EuroEwing 99 : VIDE | null | N | 330015969 | EURO-EWING |
| 330004090 | 330002025 | 1.62 | 85.7 | Curative (C) | 2013-06-13 | 2013-06-20 | Carboplatin+Fluorouracil 4 or 5 day | N | N | 330015971 | CARBO + FLUOROURACIL |
| 330004091 | 330002025 | 1.8 | 80.6 | Palliative (P) | 2014-04-07 | 2014-04-12 | CARBOPLATIN + FLUOROURACIL | 01 | N | 330015971 | CARBO + FLUOROURACIL |
| 330004092 | 330002025 | 1.57 | 54.7 | Curative (C) | 2013-04-25 | 2013-04-26 | OST Euramos 1 Closed Trial - AP | N | N | 330015971 | MAP |
| 330004093 | 330002025 | 1.77 | 66.2 | Curative (C) | 2015-02-05 | 2015-02-18 | DA | N | N | 330015971 | DA |
| 330004094 | 330002025 | 1.68 | 69 | Curative (C) | 2013-04-01 | 2013-04-14 | Cisplatin + Etoposide (3 day) | N | N | 330015971 | CISPLATIN + ETOPOSIDE |
| 330004095 | 330002025 | 1.75 | 54.3 | Neo-adjuvant (N) | null | 2015-07-14 | PAM x 2 pre-surgery (cycles 1&2) | N | N | 330015971 | MAP |
| 330004096 | 330002025 | 1.57 | 49.2 | Neo-adjuvant (N) | 2016-09-12 | 2016-09-25 | EURAMOS TRIAL | N | N | 330015971 | EURAMOS TRIAL |
| 330004097 | 330002025 | 1.56 | 49.7 | Adjuvant (A) | 2016-07-10 | 2016-07-19 | Cisplatin + Etoposide po | N | N | 330015971 | CISPLATIN + ETOPOSIDE |
| 330004098 | 330002025 | 1.7 | 75 | null | 2015-03-06 | 2015-03-24 | CETUXIMAB | 2 | N | 330015971 | CETUXIMAB |
| 330004099 | 330002025 | 1.82 | null | Palliative (P) | 2016-01-26 | 2016-02-01 | EW EuroEwing 2012 Arm A VIDE | N | N | 330015971 | EURO-EWING |
| 330004100 | 330002025 | 1.65 | 65.4 | Curative (C) | 2015-04-13 | 2015-04-20 | DA 3 + 10 | 02 | N | 330015971 | DA |
| 330004101 | 330002025 | null | 50.6 | Neo-adjuvant (N) | 2018-07-13 | 2018-07-13 | Carboplatin+Fluorouracil 4 or 5 day | null | N | 330015971 | CARBO + FLUOROURACIL |
| 330004102 | 330002026 | 1.79 | null | Palliative (P) | 2014-02-13 | 2014-02-13 | CISPLATIN + ETOPOSIDE | N | N | 330016047 | CISPLATIN + ETOPOSIDE |
| 330004103 | 330007108 | null | 86.2 | Palliative (P) | 2013-05-28 | 2013-06-18 | CAP | 02 | N | 330016049 | CAP |
| 330004104 | 330007108 | 1.62 | 93.5 | Neo-adjuvant (N) | 2016-11-05 | 2016-11-06 | Dox + HD Mtx (post PAM) | N | N | 330016049 | DOXORUBICIN + HD MTX |
| 330004105 | 330002027 | 1.7 | 49.2 | null | 2017-04-21 | 2017-04-22 | GemCarbo Days 1+8 | 02 | N | 330016051 | GEMCARBO |
| 330004106 | 330002027 | 1.63 | 93.7 | Adjuvant (A) | 2017-04-26 | 2017-05-09 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 330016051 | CISPLATIN + GEMCITABINE |
| 330004107 | 330009853 | null | null | Palliative (P) | null | 2013-10-13 | CISPLATIN + ETOPOSIDE | null | N | 330016055 | CISPLATIN + ETOPOSIDE |
| 330004108 | 330002028 | 1.81 | 41.8 | Curative (C) | null | 2016-01-27 | CETUXIMAB | N | Y | 330016083 | CETUXIMAB |
| 330004109 | 330007110 | 1.78 | 72.5 | Neo-adjuvant (N) | null | 2014-02-01 | EURAMOS TRIAL | N | Y | 330016088 | EURAMOS TRIAL |
| 330004110 | 330002029 | null | 151.7 | null | 2013-07-25 | 2013-07-25 | CISPLATIN + GEMCITABINE | N | N | 330016089 | CISPLATIN + GEMCITABINE |
| 330004111 | 330002030 | 1.57 | 125 | Adjuvant (A) | 2015-02-23 | 2015-03-07 | DA 3 + 10 | 02 | N | 330016108 | DA |
| 330004112 | 330002031 | 1.79 | 60 | Adjuvant (A) | 2014-07-14 | 2014-07-15 | Dox + HD Mtx (post PAM) | 02 | N | 330016114 | DOXORUBICIN + HD MTX |
| 330004113 | 330002032 | 1.6 | 52.4 | Neo-adjuvant (N) | 2014-01-23 | 2014-02-05 | MAP | N | N | 330016125 | MAP |
| 330004114 | 330002032 | 1.71 | 61 | Curative (C) | 2015-07-03 | 2015-07-12 | DA 3 + 10 | N | N | 330016125 | DA |
| 330004115 | 330002032 | 1.82 | 81 | Curative (C) | null | 2013-09-25 | EW EuroEwing 99 : VIDE | null | null | 330016125 | EURO-EWING |
| 330004116 | 330002032 | 1.79 | 80 | Curative (C) | 2015-11-19 | 2015-11-23 | Cetuximab 7 day (Cycle 1) | 02 | N | 330016125 | CETUXIMAB |
| 330004117 | 330002032 | 1.56 | 63 | Palliative (P) | 2013-02-07 | 2013-02-14 | CARBOPLATIN + GEMCITABINE | 02 | N | 330016125 | GEMCARBO |
| 330004118 | 330002032 | 1.78 | 74.1 | Neo-adjuvant (N) | 2017-06-26 | 2017-07-01 | EURAMOS TRIAL | N | N | 330016125 | EURAMOS TRIAL |
| 330004119 | 330002032 | 0 | 83 | Curative (C) | 2017-07-15 | 2017-08-05 | CETUXIMAB + RT | N | Y | 330016125 | CETUXIMAB + RT |
| 330004120 | 330002032 | 1.78 | 63.9 | Neo-adjuvant (N) | 2016-03-15 | 2016-03-15 | OST Euramos 1 Closed Trial - AP | null | N | 330016125 | MAP |
| 330004121 | 330002033 | 1.87 | 63.15 | Curative (C) | 2017-02-09 | 2017-02-17 | DA 3 + 10 | N | N | 330016169 | DA |
| 330004122 | 330002034 | 1.58 | 71.6 | Palliative (P) | 2015-03-12 | 2015-03-17 | GemCarbo Days 1+8 | N | N | 330016173 | GEMCARBO |
| 330004123 | 330002035 | 1.53 | 57.4 | Disease modification (D) | 2014-03-20 | 2014-03-23 | CYCLOPHOSPHAMIDE + RITUXIMAB | N | N | 330016186 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 330004124 | 330002035 | 1.79 | 28 | Curative (C) | 2015-06-24 | 2015-06-24 | Cisplatin + Etoposide (3 day) | N | N | 330016186 | CISPLATIN + ETOPOSIDE |
| 330004125 | 330002035 | 1.72 | 36.2 | Not known (9) | 2016-05-30 | 2016-07-09 | CETUXIMAB + RT | N | Y | 330016186 | CETUXIMAB + RT |
| 330004126 | 330002035 | 1.74 | 59.1 | Neo-adjuvant (N) | 2016-07-30 | 2016-07-30 | MAP | N | N | 330016186 | MAP |
| 330004127 | 330002036 | 1.4 | 59 | Curative (C) | 2016-01-07 | 2016-01-12 | Cetuximab + Radiotherapy Maint | N | N | 330016210 | CETUXIMAB + RT |